DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflicts and Continuous Submissions.

Date: December 3, 2015.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Chee Lim, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, Bethesda, MD 20892, 301–435–1850, limc4@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cardiovascular Sciences.

Date: December 9–10, 2015.

Time: 8:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Kimm Hamann, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118A, MSC 7814, Bethesda, MD 20892, 301–435–5575, hamannkj@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neuropharmacology and Channels.

Date: December 11, 2015.

Time: 9:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435–1164, custerm@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowship Review.

Date: December 11, 2015.

Time: 11:30 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Raj K Krishnaraju, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6190, Bethesda, MD 20892, 301–435–1047, kkrishna@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Laboratory Certification Program.

Date: December 11, 2015.

Time: 1:00 p.m. to 5:30 p.m.

Agenda: To review and evaluate Laboratory Certification Program applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lawerence A. Tabak, Deputy Director, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, 301–435–1047, tabak@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

SUPPLEMENTARY INFORMATION:

The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen testing for Federal Agencies.
validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

**HHS-Certified Instrumented Initial Testing Facilities**

- Dynacare
  - 6628 50th Street NW
  - Edmonton, AB Canada T6B 2N7
  - 780–784–1190
  - (Formerly: Gamma-Dynacare Medical Laboratories)

- ACM Medical Laboratory, Inc.
  - 160 Elmgrove Park
  - Rochester, NY 14624
  - 585–429–2264
  - (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories)

- Aegis Analytical Laboratories, Inc.
  - 345 Hill Ave.
  - Nashville, TN 37210
  - 615–255–2400
  - (Formerly: Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories)

- MedTox Laboratories, Inc.
  - 450 Southlake Blvd.
  - Richmond, VA 23236
  - 804–378–9130
  - (Formerly: Kroll Laboratory Specialists, Inc., Kroll Scientific Testing Laboratories, Inc.)

- Baptist Medical Center-Toxics Laboratory
  - 11401 I–30
  - Little Rock, AR 72209–7056
  - 501–202–2783
  - (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

- Clinical Reference Lab
  - 8433 Quivira Road
  - Lenexa, KS 66215–2802
  - 800–445–6917

- DrugScan, Inc.
  - 200 Precision Road, Suite 200
  - Horsham, PA 19044
  - 800–235–4890

- Dynacare*
  - 245 Pall Mall Street
  - London, ONT, Canada N6A 1P4
  - 519–679–1630
  - (Formerly: Gamma-Dynacare Medical Laboratories)

- ElSohly Laboratories, Inc.
  - 5 Industrial Park Drive
  - Oxford, MS 38655
  - 662–236–2609

- Fortes Laboratories, Inc.
  - 25749 SW Canyon Creek Road, Suite 600
  - Wilsonville, OR 97070
  - 503–486–1023

- Laboratory Corporation of America Holdings
  - 7207 N. Gessner Road
  - Houston, TX 77040
  - 713–856–8288/800–800–2387

- Laboratory Corporation of America Holdings
  - 69 First Ave.
  - Raratian, NJ 08889
  - (Formerly: Roche Biomedical Laboratories, Inc.)

- Laboratory Corporation of America Holdings
  - 1904 Alexander Drive
  - Research Triangle Park, NC 27709
  - (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc., CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

- Laboratory Corporation of America Holdings
  - 1120 Main Street
  - Southaven, MS 38671
  - 866–827–8042/800–233–6339
  - (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)

- LabOne, Inc. d/b/a Quest Diagnostics
  - 10101 Renner Blvd.
  - Lenexa, KS 66219
  - (Formerly: Quest Diagnostics Incorporated; LabOne, Inc., Center for Laboratory Services, a Division of LabOne, Inc.)

- MedTox Laboratories, Inc.
  - 402 W. County Road D
  - St. Paul, MN 55112
  - 651–636–7466/800–832–3244

- MetroLab-Legacy Laboratory Services
  - 1225 NE 2nd Ave.
  - Portland, OR 97232
  - 503–413–5295/800–950–5295

- Minneapolis Veterans Affairs Medical Center
  - Forensic Toxicology Laboratory
  - 1 Veterans Drive
  - Minneapolis, MN 55417
  - 612–725–2088

- Testing for Veterans Affairs (VA) Employees Only
  - National Toxicology Laboratories, Inc.
  - 1100 California Ave.
  - Bakersfield, CA 93304
  - 661–322–4250/800–350–3515

- One Source Toxicology Laboratory, Inc.
  - 1213 Genoa-Red Bluff
  - Pasadena, TX 77504
  - 888–747–3774
  - (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)

- Pacific Toxicology Laboratories
  - 9348 DeSoto Ave.
  - Chatsworth, CA 91311
  - 800–328–6942
  - (Formerly: Continna Hospital Airport Toxicology Laboratory)

- Pathology Associates Medical Laboratories
  - 110 West Cliff Dr.
  - Spokane, WA 99204

- Phamatech, Inc.
  - 15175 Innovation Drive
  - San Diego, CA 92128
  - 888–635–5840

- Quest Diagnostics Incorporated
  - 1777 Montreal Circle
  - Tucker, GA 30084
  - 800–729–6432
  - (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Biotechnology Laboratories)

- Quest Diagnostics Incorporated
  - 400 Egypt Road
  - Norristown, PA 19403
  - (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Biotechnology Laboratories)

- Quest Diagnostics Incorporated
  - 8401 Fallbrook Ave.
  - West Hills, CA 91304
  - 818–737–6370
  - (Formerly: SmithKline Beecham Clinical Laboratories)

- Redwood Toxicology Laboratory
  - 3700650 Westwind Blvd.
  - Santa Rosa, CA 95403
  - 800–255–2159

- Southwest Laboratories
  - 4625 E. Cotton Center Boulevard
  - Suite 177

- University of Texas Medical Branch, Clinical Laboratories; SmithKline Biotechnology Laboratories
VerDate Sep<11>2014 23:35 Nov 30, 2015 Jkt 238001 PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 E:\FR\FM\01DEN1.SGM 01DEN1

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

SUMMARY: This is a notice of the Presidential declaration of a major disaster for the State of Alaska (FEMA–4244–DR), dated October 30, 2015, and related determinations.

DATES: Effective Date: October 30, 2015.


SUPPLEMENTARY INFORMATION: Notice is hereby given that, in a letter dated October 30, 2015, the President issued a major disaster declaration under the authority of the Robert T. Stafford Disaster Relief and Emergency Assistance Act, 42 U.S.C. 5121 et seq. (the “Stafford Act”), as follows:

I have determined that the damage in certain areas of the State of Alaska resulting from a severe storm on August 27, 2015, is of sufficient severity and magnitude to warrant a major disaster declaration under the Robert T. Stafford Disaster Relief and Emergency Assistance Act, 42 U.S.C. 5121 et seq. (the “Stafford Act”). Therefore, I declare that such a major disaster exists in the State of Alaska.

In order to provide Federal assistance, you are hereby authorized to allocate from funds available for these purposes such amounts as you find necessary for Federal disaster assistance and administrative expenses.

You are authorized to provide Public Assistance in the designated area and Hazard Mitigation throughout the State. Consistent with the requirement that Federal assistance be supplemental, any Federal funds provided under the Stafford Act for Hazard Mitigation will be limited to 75 percent of the total eligible costs. Federal funds provided under the Stafford Act for Public Assistance also will be limited to 75 percent of the total eligible costs, with the exception of projects that meet the eligibility criteria for a higher Federal cost-sharing percentage under the Public Assistance Alternative Procedures Pilot Program for Debris Removal implemented pursuant to section 428 of the Stafford Act.

Further, you are authorized to make changes to this declaration for the approved assistance to the extent allowable under the Stafford Act.

The Federal Emergency Management Agency (FEMA) hereby gives notice that pursuant to the authority vested in the Administrator, under Executive Order 12148, as amended, Thomas J. Dargan, of FEMA is appointed to act as the Federal Coordinating Officer for this major disaster.

The following areas of the State of Alaska have been designated as adversely affected by this major disaster:
The North Slope Borough for Public Assistance.

All areas within the State of Alaska are eligible for assistance under the Hazard Mitigation Grant Program.

The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used for reporting and drawing funds: 97.030, Community Disaster Loans; 97.031, Coral Reef Fund; 97.032, Crisis Counseling; 97.033, Disaster Legal Services; 97.034, Disaster Unemployment Assistance (DUA); 97.046, Fire Management Assistance Grant; 97.048, Disaster Housing Assistance to Individuals and Households—Presidentially Declared Disaster Areas; 97.049, Presidentially Declared Disaster Assistance—Disaster Housing operations for Individuals and Households; 97.050, Presidentially Declared Disaster Assistance to Individuals and Households—Other Needs; 97.036, Disaster Grants—Public Assistance (Presidentially Declared Disasters); 97.039, Hazard Mitigation Grant.

W. Craig Fugate,
Administrator, Federal Emergency Management Agency.

[FR Doc. 2015–30352 Filed 11–30–15; 8:45 am]

BILLING CODE 9111–23–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA–4241–DR; Docket ID FEMA–2015–0002]

South Carolina; Amendment No. 12 to Notice of a Major Disaster Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

SUMMARY: This notice amends the notice of a major disaster declaration for the State of South Carolina (FEMA–4241–DR), dated October 5, 2015, and related determinations.

DATES: Effective Date: November 5, 2015.


SUPPLEMENTARY INFORMATION: The notice of a major disaster declaration for the State of South Carolina is hereby amended to include the following area among those areas determined to have been adversely affected by the event declared a major disaster by the President in his declaration of October 5, 2015.

Spartanburg County for Public Assistance (already designated for Individual Assistance).

The following Catalog of Federal Domestic Assistance Numbers (CFDA) are to be used